Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera Inc (NQ: NTRA )

128.20 -1.64 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera Inc

< Previous 1 2 3 4 5 6 Next >
Natera to Report its Third Quarter 2023 Results on November 8
From Natera, Inc.
Via Business Wire
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
From Natera, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
From Natera, Inc.
Via Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
From Natera, Inc.
Via Business Wire
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
From Natera, Inc.
Via Business Wire
Natera Submits First PMA Module to the FDA for Signatera™
From Natera, Inc.
Via Business Wire
Natera Announces Senior Leadership Appointments
From Natera, Inc.
Via Business Wire
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Natera Announces Pricing of $250 Million Follow-On Offering
From Natera, Inc.
Via Business Wire
Natera Launches Proposed Follow-On Offering
From Natera, Inc.
Via Business Wire
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
From Natera, Inc.
Via Business Wire
Natera Reports Second Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera Files Patent Infringement Suit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2023 Results on August 3rd
From Natera, Inc.
Via Business Wire
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
From Natera, Inc.
Via Business Wire
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
Natera Announces Commercial Payor Coverage for Signatera™
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.